An Analysis of HER-2/neu, ERCC1, and GST-pi in Advanced Non-Small Cell Lung Cancer Patients Who are Treated with Platinum-based Chemotherapy.
- Author:
Kyung Jin SEO
1
;
Byoung Yong SHIM
;
Hoon Kyo KIM
;
Ji Han JUNG
;
Jinyoung YOO
;
Seok Jin KANG
;
Kyo Young LEE
Author Information
1. Department of Pathology, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea. jinyyoo@vincent.cuk.ac.kr
- Publication Type:Original Article
- Keywords:
Carcinoma, Non-small cell lung;
Genes, HER-2;
ERCC1 protein, human;
Glutathione S-transferase pi;
Cisplatin
- MeSH:
Humans;
Biopsy;
Lung Neoplasms
- From:Korean Journal of Pathology
2008;42(6):327-334
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Platinum-based chemotherapy has shown to be an effective first-line treatment for patients with advanced stage, unresectable non-small cell lung cancer (NSCLC). We evaluated the response rate to combination chemotherapy with cisplatin and taxane, and the significance of the HER-2/neu, ERCC1, and GST-pi status as predictive markers for the tumor response. METHODS: The HER-2/neu, ERCC1, and GST-pi status were analyzed in the biopsy specimens obtained from 35 patients with advanced stage NSCLC prior to cisplatin plus either paclitaxel or docetaxel chemotherapy. RESULTS: The response rate of the tumors to combination chemotherapy was 62.9% (22/35). HER-2/neu was amplified in 51.4% (18/35) of the tumors, and this was observed exclusively in patients with progressive disease (p=0.014). ERCC1 was overexpressed in 77.2% of the specimens (27/35), and this showed a tendency to correlate with the tumor response (p=0.057). GST-pi was detected in 85.7% of the specimens (30/35). Seventy-seven percent of the patients with a negative HER-2/neu and positive ERCC1 status showed a partial response, which was in contrast to only a 25% response rate for the patients with a positive HER-2/neu and negative ERCC1 status (p=0.006). The overall survival was prolonged in the patients without HER-2/neu amplification (15 vs 8.5 months, respectively, p=0.008). On multivariate analysis, the HER-2/neu status remained the significant predictor of survival (p=0.005). CONCLUSIONS: A combination of the ERCC1, HER-2/neu status may define a subset of patients with the most favorable response to combination chemotherapy regimens for treating advanced NSCLC.
